Page last updated: 2024-12-08

isomaltotriose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isomaltotriose: RN given refers to all D-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isomaltotriose : A glucotriose consisting of two alpha-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->6) glycosidic bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439668
MeSH IDM0132106

Synonyms (19)

Synonym
glc(a1-6)glc(a1-6)glc
N_FULL_30000000000000_GS_3549
alpha-d-glucopyranosyl-(1->6)-alpha-d-glucopyranosyl-(1->6)-d-glucose
alpha-d-gluco-hexopyranosyl-(1->6)-alpha-d-gluco-hexopyranosyl-(1->6)-d-gluco-hexopyranose
3371-50-4
isomaltotriose
C02160
isomaltosaccharide
isomaltotriose, >=98% (tlc)
isomaltotriose, dp3, analytical standard
I0329
FBJQEBRMDXPWNX-FYHZSNTMSA-N
W-202383
mfcd00070623
(3r,4s,5s,6r)-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)methyl)tetrahydro-2h-pyran-2-yloxy)methyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
455-50-5
(3r,4s,5s,6r)-6-((((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
T72321
alpha-d-glucosyl-[1->6]-alpha-d-glucosyl-[1->6]-d-glucose
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glucotrioseAny trisaccharide composed of 3 glucose moieties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (37.50)18.2507
2000's3 (18.75)29.6817
2010's7 (43.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.38 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]